HCW Biologics is trading 43.37% up at $2.38 after announcing pricing for a $1.5 million private placement with an existing stockholder. - The financing includes 903,614 pre-funded warrants priced at $1.6599 per unit, plus potential common warrants subject to stockholder approval. - Proceeds are intended to support HCW9302 trials, IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes. - The announcement is the clearest identified company-specific catalyst for the September 24, 2026 move.